{"org_id": "T004848935", "org_name_cn": "康希诺生物股份公司", "org_short_name_cn": "康希诺", "org_name_en": "Cansino Biologics Inc.", "org_short_name_en": "CanSinoBIO", "main_operation_business": "研发、生产和商业化符合中国及国际标准的创新型疫苗。", "operating_scope": "　　化学药品、生物药品、疫苗和诊断试剂的研发、技术转让，生产（凭许可证开展经营活动），并提供技术咨询服务；化学品、生物制品及耗材的批发（食品、药品、危险化学品及易燃、易爆、易制毒品除外）、进出口。（依法须经批准的项目，经相关部门批准后方可开展经营活动）。", "district_encode": "120110", "org_cn_introduction": "康希诺生物股份公司的主营业务为研发、生产和商业化符合中国及国际标准的创新型疫苗。公司主要产品为埃博拉病毒病疫苗、脑膜炎疫苗、百白破疫苗、肺炎疫苗、结核病疫苗、带状疱疹疫苗。公司推进了一系列创新疫苗的研发，研发管线涵盖预防脑膜炎、埃博拉病毒病、百白破、肺炎、结核病、带状疱疹等多个临床需求量较大的疫苗品种。其中埃博拉病毒病疫苗已经完成新药注册，两个脑膜炎球菌疫苗产品已经提交NDA并获受理，百白破、肺炎、结核病疫苗已经进入了临床试验阶段，公司获得了“天津瞪羚企业卓越创新奖”、“中国最具成长力科技创新型医药企业”、“天津市呼吸道细菌重组及结合疫苗企业重点实验室”等多项荣誉。", "legal_representative": "宇学峰", "general_manager": "崔进", "secretary": "崔进", "established_date": 1231776000000, "reg_asset": 247449899.0, "staff_num": 1263, "telephone": "86-22-58213766", "postcode": "300457", "fax": "86-22-58213626", "email": "ir@cansinotech.com", "org_website": "www.cansinotech.com.cn", "reg_address_cn": "天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420", "reg_address_en": "401-420\r\n4th Floor\r\nBiomedical Park\r\n185 South Avenue\r\nTEDA West District\r\nTianjin\r\nPRC", "office_address_cn": "天津市东丽区经济技术开发区西区南大街185号西区生物医药园", "office_address_en": "401-420\r\n4th Floor\r\nBiomedical Park\r\n185 South Avenue\r\nTEDA West District\r\nTianjin\r\nPRC", "currency_encode": "019001", "currency": "CNY", "listed_date": 1597248000000, "provincial_name": "天津市", "actual_controller": "朱涛 (7.49%)，Xuefeng YU (7.22%)，Dongxu QIU (6.92%)，Helen Huihua MAO (6.60%)", "classi_name": "民营企业", "pre_name_cn": null, "chairman": "宇学峰", "executives_nums": 18, "actual_issue_vol": 24800000.0, "issue_price": 209.71, "actual_rc_net_amt": 4979465100.0, "pe_after_issuing": null, "online_success_rate_of_issue": 0.03356555, "affiliate_industry": {"ind_code": "BK0042", "ind_name": "生物制品"}}